CN110269877A - Application of the Fat Emulsion in the liquid barrier anti-blocking agent drug of prevention peritoneal adhesion - Google Patents
Application of the Fat Emulsion in the liquid barrier anti-blocking agent drug of prevention peritoneal adhesion Download PDFInfo
- Publication number
- CN110269877A CN110269877A CN201910301514.3A CN201910301514A CN110269877A CN 110269877 A CN110269877 A CN 110269877A CN 201910301514 A CN201910301514 A CN 201910301514A CN 110269877 A CN110269877 A CN 110269877A
- Authority
- CN
- China
- Prior art keywords
- fat emulsion
- adhesion
- blocking agent
- liquid barrier
- peritoneal adhesion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses application of the Fat Emulsion in the liquid barrier anti-blocking agent drug of prevention peritoneal adhesion.The present invention has excavated out new medical value to Fat Emulsion, is used for pelvic cavity flushing and postoperative abdominopelvic cavity retains, can be used as liquid barrier anti-blocking agent, to open up a new purposes for Fat Emulsion.Fat Emulsion itself does not have an impact wound healing, does not also generate other influences to body, and do not promote bacterial growth, plays prevention peritoneal adhesion by forming hydrophobic protective film on surgical wound surface.Fat Emulsion can substantially reduce inflammatory reaction and exudation compared with non-medication group, protect serous coat, can be substantially reduced the generation of peritoneal adhesion and intestinal adhesion, early postoperation effect is particularly evident.
Description
Technical field
The present invention relates to clinical drug application fields.More particularly to Fat Emulsion is anti-sticking in the liquid barrier of prevention peritoneal adhesion
The even application in agent drug.
Background technique
Abdominal cavity adhesion is the common complication of abdomen and operation on pelvis, and incidence is in gynecologic operation up to 97%, in abdomen
Portion's operation is 67%-93%, and complication includes chronic abdominopelvic cavity pain, intercourse pain, infertile, abdominal distension, intestinal obstruction and performs the operation again
Difficulty etc..The product for having multiple abdominal cavity local uses at present gets the Green Light in the U.S., Japan is applied to clinic, but due to using
The defects of crowd is limited, there are complication, malabsorption after use, cannot extensive clinical application.
Peritoneal adhesion is body after by external irritant, damages a kind of inflammatory reaction that peritonaeum and its basilar memebrane occur,
It is a kind of self-protection and the repair mechanism of body.Local exudate condenses to form adhesion in 3 hours after injury, is initially temporarily
Shi Xingke voluntarily dissolves, and when being not dissolved such as adhesion there are 3 days or more, fibroblast infiltration and new capillary vessel are long
Enter, firm fibrous adherence is caused to be formed.The precautionary measures for clinically preventing peritonaeum intestinal adhesion include: to reduce peritonaeum wound in art
Wound is isolated with ancillary drug (reduce inflammatory reaction, inhibit agglutinating reaction, promotion fibrinolysis) and peritonaeum.State at present
It is inside and outside not have effective method clinically once application enhancements surgical procedure so far, avoid serous damage or mitigate serous coat abrasion etc.,
Existing drug fails to effectively inhibit peritoneal adhesion.Therefore, research and development effectively prevent postsurgical peritoneal and have no toxic side effect in vivo
And the hot spot that domestic and foreign scholars study can be become by the ideal biological isolated material or drug that internal degradation absorbs.
The liquid barrier anti-blocking agent of clinical application is since absorption of the peritonaeum to the class I liquid I is too fast, to adhesion prevention effect
Time is too short, and curative effect is not also affirmed.Part isotonic saline solution, crystalloid fluid and macromolecular substances etc., curative effect cannot still be affirmed.
The solid barrier anti-blocking agent of clinical application lowers treatment since blood, the body fluid by intraperitoneal exudation are influenced
Effect, some products need fixed and nonabsorable, occur after Some dosage forms clinical use inconvenience or even some launch
Serious adverse reaction is withdrawn from the market.
Summary of the invention
The object of the present invention is to provide new application of the Fat Emulsion in the liquid barrier anti-blocking agent of prevention peritoneal adhesion.Rouge
Fat cream is rinsed for pelvic cavity in art and postoperative abdominopelvic cavity retains, and strong operability is quick, and has no toxic side effect.Fat Emulsion has
Ready-made compound preparation finished product, is widely used in clinical treatment, supplements energy for patient.Present invention discover that Fat Emulsion is to preventing and control
Treating Abdominal or pelvic adhesion plays the role of feeling quite pleased.
Fat Emulsion is compound preparation finished product, component are as follows: injection soybean oil, injection median chain triglyceride oil, injection
Lecithin, glycerol for injection, enuatrol, sodium hydroxide, water for injection, enuatrol etc..It is refined natural for injecting soybean oil
Product, the triglyceride of pufa-containing.Fat Emulsion (soybean oil content 5%-95%, the soybean oil of various ratios
Can be by animal oil or other vegetable oil replacements) it can be used.
Patient (such as pathologic hyperlipemia) lipoid nephrosis of fat metabolism exception, severe liver injury or acute pancreatitis companion
Hyperlipemia then disables this product.If patient suffers from ketoacidosis or anoxic, embolism or shock then should more be disabled.Egg, beans allergy
Person's disabling.
The beneficial effects of the present invention are:
(1), the present invention has excavated out new medical value to Fat Emulsion, is used for pelvic cavity flushing and postoperative abdominopelvic cavity retains,
It can be used as liquid barrier anti-blocking agent, to open up a new purposes for Fat Emulsion.The Inspiration Sources of the application are in pelvic cavity
Abdominal or pelvic adhesion will not usually occur for the patient for occurring chyle transudation after lymph node dissection.The reason is that chyle liquid main component is sweet
Oily three esters, in 1 week of the postoperative inflammatory exudation of tumor radical cure, the chyle liquid of leakage forms one layer of hydrophobic film, is covered on basin abdomen
Cavity tissue organ serosal surface is isolated the surface of a wound, and enhances the wriggling of intestinal tube, glues so as to avoid between intestinal tube and peritonaeum or intestinal tube
Formation even.After a week, inflammatory exudation stops, it is no longer necessary to protecting, body has healed, to reach the work of preventing adhesions
With.
(2) Fat Emulsion main component is soybean oil, glycerol, lecithin etc., cannot be dissolved in water, can be attached to abdominopelvic cavity extensively
Chamber, serous coat and big net film surface form one layer of protective film.Such as it is applied to clinical operation, one layer can be formed on surgical wound surface and dredged
Aqueous film protects the coarse surface of a wound, lubrication isolation intestinal loop and peritonaeum, has the function of preventing the mutual adhesion of intestinal tube, be conducive to intestines
The recovery of wriggling and offer energy etc..
(3) Fat Emulsion itself does not have an impact wound healing, does not also generate other influences to body, and does not promote thin
Bacterium growth, plays prevention peritoneal adhesion by forming hydrophobic protective film on surgical wound surface.
(4) Fat Emulsion can substantially reduce inflammatory reaction and exudation compared with non-medication group, protect serous coat, can be substantially reduced abdomen
The generation of film coalescence and intestinal adhesion, early postoperation effect are particularly evident.
Specific embodiment
In order to make the objectives, technical solutions, and advantages of the present invention clearer, following embodiment, to the present invention into one
Step is described in detail, and described specific real case is only used to explain the present invention, but is not used in the restriction present invention.
Operating method
After abdominopelvic cavity is performed the operation, gives Fat Emulsion 250-500ml abdominopelvic cavity and rinse and retain, the ultra-fine pelvic draining pipe clamp of indwelling
It closes, color ultrasound surveys abdominopelvic cavity Fat Emulsion surplus after 2-3 days, and Fat Emulsion 250ml can be perfused again according to state of an illness needs.Postoperative record
Two groups of patient's blood routines, blood coagulation, liver function, blood lipid, symptom, adverse reactions, 1 week, January and outpatient service further consultation in March understand symptom and change
Kind situation and check pelvic cavity color ultrasound or CT etc., determine objective curative effect.
It is included in standard: the patient that abdominopelvic cavity need to undergo surgery；Preoperative blood routine, blood coagulation, electrolyte and hepatic and renal function etc. are equal
In normal range (NR).The program that entire test process follows meets Jinmen First People's Hospital (Hubei affiliated hospital, ethnic university)
The prepared ethical standard of the human trial committee simultaneously obtains the approval of the committee, and the preoperative informed consent of study subject is simultaneously
Sign the informed consent form of committee formulation.
Our hospital is randomly divided into 2 groups: test group 20 in 01 month 2018 to 12 lunar basin abdominal operation patient 40, Yu Shoushu
After routinely give Fat Emulsion 250-500ml abdominopelvic cavity rinse and retain；Control group 20, do not have to after Yu Shoushu any
The preparation that prevents adhesion directly closes abdomen.As the result is shown: two groups of patient's blood routines, blood coagulation, liver function, blood lipid and adverse reaction etc. ratio
Compared with no significant difference (P > 0.05)；Compared with the control group, without an example Abdominal or pelvic adhesion occurs for test group, and patient symptom changes
Kind aspect (P < 0.05) substantially reduced compared with control group.
Case one
Symptom: discontinuity lower abdominal pain.Gynaecological examination: lower abdomen tenderness, no rebound tenderness.Auxiliary inspection: color ultrasound or CT prompt pelvic cystic
Mass.Laparoscopic approach prompts pelvic adhesion, encapsulated effusion, operation excision adhesive band.After Fat Emulsion, symptom after 1 week
It disappears, color ultrasound and CT pelvic cavity no abnormality seen is checked after January and March.
Case two
Symptom: female acyesis.Auxiliary inspection: color ultrasound prompts bilateral salpingo ponding；HSG prompts bilateral salpingo ponding.Laparoscope is visited
Prompt pelvic adhesion, bilateral salpingo hydrops are looked into, operation excision adhesive band, it is postoperative that both fallopian tubes stoma leads to liquid.Use Fat Emulsion
Afterwards, color ultrasound pelvic cavity no abnormality seen is checked after January and March.Patient's pregnancy carrys out our hospital's inspection after 4 months.
The peritoneal adhesions such as gynaecology, department of general surgery, Urology Surgery or intestinal adhesion complication happen occasionally at present, still annoying operation
Section doctor, by the way that, using the risk for avoiding complication and performing the operation again, doctor is no longer this reason in the art of Fat Emulsion
And worry.
The foregoing is merely preferable case study on implementation of the invention, are not intended to restrict the invention, all of the invention
Made any modifications, equivalent replacements, and improvements etc., is all included in the scope of protection of the present invention within spirit and principle.
The Fat Emulsion (soybean oil content 5%-95%, soybean oil can be by animal oil or other vegetable oil replacements) of various ratios exists
Application in terms of prevention and treatment adhesion should all be included in the protection scope of the present invention.
Claims (1)
1. application of the Fat Emulsion in the liquid barrier anti-blocking agent drug of prevention peritoneal adhesion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910301514.3A CN110269877A (en) | 2019-04-16 | 2019-04-16 | Application of the Fat Emulsion in the liquid barrier anti-blocking agent drug of prevention peritoneal adhesion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910301514.3A CN110269877A (en) | 2019-04-16 | 2019-04-16 | Application of the Fat Emulsion in the liquid barrier anti-blocking agent drug of prevention peritoneal adhesion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110269877A true CN110269877A (en) | 2019-09-24 |
Family
ID=67959388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910301514.3A Pending CN110269877A (en) | 2019-04-16 | 2019-04-16 | Application of the Fat Emulsion in the liquid barrier anti-blocking agent drug of prevention peritoneal adhesion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110269877A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113244400A (en) * | 2021-05-21 | 2021-08-13 | 华北理工大学 | Application of C5aRA in preparation of product for treating and/or preventing abdominal cavity adhesion |
| CN114668898A (en) * | 2022-03-25 | 2022-06-28 | 中山大学 | Application of fat emulsion in preparation of wound repair material |
| CN114886922A (en) * | 2022-05-25 | 2022-08-12 | 温州医科大学附属第一医院 | Medicine containing fat micro-segment and application thereof in treatment of chronic wound surface difficult to heal |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1385152A (en) * | 2002-05-28 | 2002-12-18 | 郝易风 | Antiadhesion agent for preventing abdominal organs from adhesion |
-
2019
- 2019-04-16 CN CN201910301514.3A patent/CN110269877A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1385152A (en) * | 2002-05-28 | 2002-12-18 | 郝易风 | Antiadhesion agent for preventing abdominal organs from adhesion |
Non-Patent Citations (2)
| Title |
|---|
| 王保春等: "预防术后腹膜粘连的研究进展 ", 《山东医药》 * |
| 田小林: "应用脂肪乳剂腹腔灌注法防治腹腔粘连22例", 《华夏医学》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113244400A (en) * | 2021-05-21 | 2021-08-13 | 华北理工大学 | Application of C5aRA in preparation of product for treating and/or preventing abdominal cavity adhesion |
| CN114668898A (en) * | 2022-03-25 | 2022-06-28 | 中山大学 | Application of fat emulsion in preparation of wound repair material |
| CN114886922A (en) * | 2022-05-25 | 2022-08-12 | 温州医科大学附属第一医院 | Medicine containing fat micro-segment and application thereof in treatment of chronic wound surface difficult to heal |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110269877A (en) | Application of the Fat Emulsion in the liquid barrier anti-blocking agent drug of prevention peritoneal adhesion | |
| Catalano et al. | Biliary infections: spectrum of imaging findings and management | |
| Wen et al. | Diagnosis and management against the complications of human cystic echinococcosis | |
| Franko et al. | A rare variation of Amyand's hernia | |
| Giorgio et al. | Long-term results of percutaneous treatment of hydatid liver cysts: a single center 17 years experience | |
| Doubilet et al. | Surgical management of injury to the pancreas | |
| Kouskos et al. | Uncommon locations of hydatid cysts | |
| Etlik et al. | Abdominal hydatid disease: long‐term results of percutaneous treatment | |
| Boccardo et al. | The lymphatics in the pathophysiology of thoracic and abdominal surgical pathology: immunological consequences and the unexpected role of microsurgery | |
| Kumar et al. | Management of hydatid disease of the liver. | |
| Tacyildiz et al. | Diagnosis and surgical treatment of intrabiliary ruptured hydatid disease of the liver | |
| Hotta et al. | Spontaneous rupture of a simple hepatic cyst: report of a case | |
| Yucesoy et al. | Radiologic findings and percutaneous treatment of a rare giant soft tissue hydatid cyst | |
| Dong et al. | Management strategy for congenital choledochal cyst with co-existing intrahepatic dilation and aberrant bile duct as well as other complicated biliary anomalies | |
| Aurello et al. | Management of primary epiploic appendagitis in the laparoscopic era | |
| Singh et al. | Secondary inguinal hydatidosis mimicking irreducible inguinal hernia: report of a rare case | |
| Chawla et al. | Imaging features of disseminated peritoneal hydatidosis before and after medical treatment | |
| Kim et al. | Intrahepatic pancreatic pseudocyst complicated by pancreatitis: a case report | |
| Karahan et al. | Continuous ambulatory peritoneal dialysis: CT peritoneography findings and assessment of related clinical complications | |
| Mihmanli et al. | The surgical management of hydatid cyst of the liver: what is new? | |
| Florea | Spontaneous external fistula of a hydatid liver cyst in a diabetic patient | |
| Prasuna et al. | Management of rare and atypical inguinal hernias: our experience at a tertiary care centre | |
| Sönmez et al. | Clear cystic fluid in hepatic hydatidosis does not rule out communication between cysts and the biliary system | |
| Shemesh et al. | Radiologic and endoscopic appearance of intrabiliary rupture of hydatid liver disease | |
| Yang et al. | Treatment of complicated hepatic cystic hydatidosis with intrabiliary rupture by pericystectomy in combination with Roux-en-Y hepaticojejunostomy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190924 |
|
| WD01 | Invention patent application deemed withdrawn after publication |